Non-Hormonal Treatment Options for Perimenopause

Hormone replacement therapy is the most effective treatment for many perimenopause symptoms. That is a fact worth stating plainly, because this article is not about dismissing HRT. It is about recognizing that HRT is not the right choice for everyone and that women who cannot or choose not to take hormones still deserve effective, well-studied options and honest information about what those options can do.

There are many valid reasons to explore non-hormonal treatments. You may have a personal history of breast cancer that makes estrogen therapy inadvisable. You may have a clotting disorder. You may simply prefer to try other approaches first. Or you may already be using HRT and want additional tools for symptoms it is not fully addressing.

Whatever your reason, the landscape of non-hormonal treatments has expanded considerably in recent years. Some of these options have strong clinical evidence behind them. Others have more modest support. This article will be clear about the difference so you can make informed decisions with your healthcare provider.

SSRIs and SNRIs: Antidepressants That Treat Hot Flashes and Mood

Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are best known as antidepressants, but research has shown that several of these medications reduce hot flashes independently of their mood effects. Despite the name, this is not about the outdated myth that perimenopause is “just depression”; these medications target specific neurological pathways involved in temperature regulation. They appear to work by stabilizing the thermoregulatory center in the brain, which becomes more sensitive to small temperature changes during the menopausal transition. Mayo Clinic's overview of perimenopause provides additional context on how these temperature-regulation changes develop.

Paroxetine (Brisdelle) is the only SSRI that carries a specific FDA approval for the treatment of moderate to severe vasomotor symptoms associated with menopause. At a dose of 7.5 mg per day, which is lower than typical antidepressant dosing, it reduces hot flash frequency by roughly 33 to 65 percent in clinical trials. This is less effective than HRT, which typically achieves 75 to 90 percent reduction, but it represents a meaningful improvement for many women.

Other SSRIs and SNRIs used off-label for hot flashes include:

• Venlafaxine (Effexor): One of the most studied non-hormonal options for hot flashes. At doses of 37.5 to 150 mg per day, it reduces hot flash frequency by approximately 30 to 60 percent. It also helps with mood and anxiety, making it particularly useful for women experiencing both vasomotor and emotional symptoms. Evidence level: strong, from multiple randomized controlled trials.
• Desvenlafaxine (Pristiq): The active metabolite of venlafaxine with similar efficacy for hot flashes and fewer drug interactions. Doses of 50 to 150 mg per day have been studied. Evidence level: strong.
• Escitalopram (Lexapro): At 10 to 20 mg per day, it has shown modest hot flash reduction of roughly 50 percent and provides meaningful relief for anxiety and mood instability. Evidence level: moderate to strong.
• Citalopram (Celexa): Similar to escitalopram but with slightly less robust data for hot flashes specifically. Evidence level: moderate.

Important considerations: SSRIs and SNRIs can cause side effects including nausea, headache, dizziness, sexual dysfunction, and sleep disturbance, particularly during the first few weeks. They should be tapered gradually rather than stopped abruptly. If you are taking tamoxifen for breast cancer, paroxetine and fluoxetine should be avoided because they inhibit the enzyme that converts tamoxifen to its active form. Venlafaxine or desvenlafaxine are better choices in that situation.

For women dealing with both vasomotor symptoms and perimenopausal mood and anxiety changes, SSRIs and SNRIs offer a practical advantage: one medication can address multiple concerns simultaneously. This dual benefit explains why many clinicians reach for this class first when considering non-hormonal approaches.

Gabapentin and Pregabalin: Relief for Hot Flashes and Sleep

Gabapentin, originally developed as an anticonvulsant, has become one of the most commonly prescribed non-hormonal treatments for hot flashes. It reduces hot flash frequency by approximately 45 to 70 percent in clinical trials, with benefits typically appearing within the first week or two.

One of gabapentin’s notable advantages is its effect on sleep. Because it promotes drowsiness, clinicians often prescribe it as a single bedtime dose (typically 300 to 900 mg), which addresses both night sweats and the insomnia that so often accompanies perimenopause. For women whose sleep disruption is a primary complaint, gabapentin can serve double duty in a way that few other treatments can.

Side effects include drowsiness, dizziness, and mild cognitive fogginess. These effects are most pronounced when treatment begins and often diminish over time. Starting at a low dose and increasing gradually helps minimize these issues. Gabapentin is not habit-forming, though it should be tapered rather than stopped abruptly after extended use.

Pregabalin (Lyrica) works through a similar mechanism and has also shown efficacy for hot flashes in clinical trials, reducing their frequency by approximately 50 to 65 percent. Pregabalin may be slightly better tolerated than gabapentin in some women, and it also carries the benefit of improving sleep quality. It is a controlled substance in many jurisdictions, which is an important practical consideration. Both medications are considered to have strong evidence from multiple randomized controlled trials.

Clonidine: A Modest but Sometimes Useful Option

Clonidine is a blood pressure medication that has been used for decades to treat hot flashes. It works by reducing the reactivity of blood vessels and calming the sympathetic nervous system, which is involved in the flushing response.

It is modestly effective, reducing hot flash frequency by approximately 20 to 40 percent. This is a smaller effect than SSRIs, gabapentin, or fezolinetant, which is why clonidine is generally considered a second or third line option. Side effects can include dry mouth, drowsiness, constipation, and low blood pressure. It needs to be tapered slowly because abrupt discontinuation can cause a rebound increase in blood pressure.

Clonidine may be particularly useful for women who also have high blood pressure, since it can address both concerns simultaneously. It is also sometimes considered when other non-hormonal options have been tried without sufficient relief or when drug interactions limit the use of SSRIs or gabapentin. The evidence base is moderate, consisting of older, generally smaller studies with consistent but modest effects.

Fezolinetant (Veozah): The Newest FDA-Approved Option

Fezolinetant, sold under the brand name Veozah, represents a genuinely new class of treatment for hot flashes. Approved by the FDA in May 2023, it is a neurokinin 3 (NK3) receptor antagonist, meaning it works by blocking the specific brain pathway responsible for triggering hot flashes during hormonal transitions. Unlike SSRIs and gabapentin, which were borrowed from other therapeutic areas, fezolinetant was designed specifically for vasomotor symptoms.

In clinical trials (the SKYLIGHT studies), fezolinetant at 45 mg once daily reduced hot flash frequency by approximately 60 to 65 percent and significantly decreased their severity. Benefits were apparent within the first week and sustained through 52 weeks of follow-up. This targeted mechanism represents a major step forward in non-hormonal treatment because it addresses the root neurological process behind hot flashes rather than working indirectly through other pathways.

Because it acts on the NK3 pathway rather than hormonal pathways, fezolinetant is appropriate for women with hormone-sensitive conditions such as breast cancer. This makes it a particularly important addition to the treatment landscape for breast cancer survivors and others who cannot use estrogen.

Fezolinetant requires liver function monitoring. Liver enzyme elevations were seen in a small percentage of clinical trial participants, and the medication is contraindicated in women with severe liver impairment. Your clinician will check liver function before starting treatment and periodically thereafter. Common side effects include abdominal pain, diarrhea, and insomnia, though most participants in trials tolerated the medication well.

The primary drawback at present is cost. As a newer branded medication, Veozah may not be covered by all insurance plans, and the out-of-pocket price can be significant. A patient savings program is available through the manufacturer. For women who can access it, however, fezolinetant offers the strongest targeted, non-hormonal approach to hot flashes currently available.

Evidence level: strong, from large randomized controlled trials (SKYLIGHT 1, 2, and 4).

Cognitive Behavioral Therapy for Menopause (CBT-Meno)

Not every effective treatment comes from a prescription pad. Cognitive behavioral therapy adapted specifically for menopause (sometimes called CBT-Meno) has accumulated strong evidence for reducing the impact of several perimenopause symptoms. For a detailed look at these approaches, see our full guide to behavioral and mind-body therapies. This is not generic talk therapy. It is a structured, time-limited program that targets specific thought patterns and behaviors that worsen the experience of symptoms like hot flashes, insomnia, and mood changes.

CBT for Hot Flash Distress

Here is an important distinction that CBT research has helped clarify: the frequency of hot flashes and the distress they cause are not the same thing. Two women can have the same number of hot flashes per day, yet one finds them manageable while the other finds them debilitating. CBT does not reduce the actual number of hot flashes you experience. What it does, and what large clinical trials have confirmed, is significantly reduce how bothersome and disruptive those hot flashes feel.

A landmark UK trial led by Professor Myra Hunter found that CBT delivered in group format reduced hot flash interference with daily life by approximately 50 percent. Participants reported that hot flashes felt less intense, less distressing, and less disruptive to their work, sleep, and social lives. These improvements were durable, persisting well beyond the end of the treatment program. This research has been replicated across multiple studies and populations.

The therapy works by helping women identify and modify the catastrophic thoughts that amplify hot flash distress (for example, “Everyone is looking at me,” or “I cannot handle this”) and by introducing practical coping behaviors like paced breathing and environmental management.

CBT-I for Insomnia

Cognitive behavioral therapy for insomnia (CBT-I) is a structured program that addresses the thoughts, behaviors, and habits that perpetuate poor sleep. Unlike a sleeping pill, CBT-I treats the root causes of insomnia rather than masking the symptom. It is considered the first-line treatment for chronic insomnia by the American College of Physicians, ahead of any medication.

For perimenopausal women, insomnia is often a tangled problem. Night sweats wake you up, then anxiety about not sleeping keeps you awake, and then the habits you develop in response (spending too long in bed, napping, scrolling your phone at 3 a.m.) make the insomnia self-sustaining even on nights when you do not have night sweats. CBT-I addresses the behavioral and cognitive components directly.

A typical CBT-I program runs four to eight sessions and includes sleep restriction therapy (temporarily limiting time in bed to consolidate sleep), stimulus control (retraining your brain to associate bed with sleep), cognitive restructuring (addressing catastrophic thoughts about sleep), and relaxation training. The MsFLASH study demonstrated that telephone-delivered CBT-I produced durable improvements in insomnia severity specifically in menopausal women. CBT-I can be delivered in person, by telephone, or through validated digital programs.

CBT for Perimenopause Mood and Anxiety

Standard cognitive behavioral therapy has strong evidence for treating depression and anxiety in the general population, and the evidence for its use during the menopausal transition specifically is growing. Perimenopause can trigger new mood symptoms or worsen pre-existing ones. The hormonal instability of this period makes some women more vulnerable to depressive episodes, even if they have never experienced depression before.

CBT helps by identifying and challenging negative thought patterns, developing healthier coping strategies, and building behavioral activation. For perimenopausal women, therapy can also address the grief, identity shifts, and body image changes that often accompany this life stage. Research supports its effectiveness both as a standalone treatment and in combination with medication.

Evidence level: strong for insomnia and mood; moderate to strong for hot flash distress reduction.

Vaginal Moisturizers and Local Vaginal Estrogen

Vaginal dryness, irritation, pain during intercourse, and recurrent urinary tract infections are among the most common and most undertreated symptoms of perimenopause and menopause. These symptoms result from the thinning and drying of vaginal and urethral tissue as estrogen levels decline, a condition now called genitourinary syndrome of menopause (GSM). Unlike hot flashes, which often improve over time, GSM tends to worsen progressively without treatment.

Vaginal Moisturizers and Lubricants

Over-the-counter vaginal moisturizers such as Replens, Hyalo GYN, and Good Clean Love BioCare are designed to be used regularly, typically two to three times per week, to maintain vaginal moisture. They are not the same as lubricants. Moisturizers adhere to the vaginal wall and provide sustained hydration, while lubricants reduce friction during intercourse. Both have their place.

Clinical studies show that vaginal moisturizers can improve symptoms of vaginal dryness and discomfort, though they are generally less effective than vaginal estrogen for moderate to severe symptoms. They are a reasonable first-line approach for mild symptoms and a useful complement to other treatments. For lubricants, water-based and silicone-based products are both options. Avoid products with glycerin, parabens, or fragrances, as these can cause irritation. Products with an osmolality close to that of vaginal tissue (iso-osmolar) are gentler and less likely to cause discomfort.

Low-Dose Vaginal Estrogen: Local, Not Systemic

Low-dose vaginal estrogen deserves discussion here because, while it is technically a hormonal product, it works locally rather than systemically. The estrogen in vaginal creams, rings, and tablets is absorbed primarily by the vaginal and urethral tissue, with minimal absorption into the bloodstream. Systemic estrogen levels remain within the postmenopausal range for most women using these products.

This distinction matters enormously for women who have been told they cannot use hormone therapy. Many oncologists now consider low-dose vaginal estrogen acceptable even for breast cancer survivors, particularly those not taking aromatase inhibitors, though this should always be discussed with your cancer care team. The American College of Obstetricians and Gynecologists and the North American Menopause Society both support the use of low-dose vaginal estrogen for GSM in most women, including many with contraindications to systemic HRT.

Vaginal estrogen is the most effective treatment for GSM. It restores vaginal tissue thickness, improves lubrication, reduces urinary symptoms, and decreases the frequency of urinary tract infections. Benefits typically begin within a few weeks, with full effects at about three months.

When Non-Hormonal Options Make More Sense Than HRT

Non-hormonal treatments are not simply a consolation prize for women who cannot take hormones. There are several clinical situations where they may genuinely be the better choice:

• History of hormone-sensitive breast cancer: Systemic estrogen is generally contraindicated. Fezolinetant, SSRIs, SNRIs, gabapentin, and CBT all offer real relief without hormonal exposure.
• History of blood clots or clotting disorders: While transdermal estrogen carries less clotting risk than oral forms, some women and clinicians prefer to avoid hormonal options entirely. Non-hormonal treatments eliminate this concern.
• Predominantly mood-related symptoms: If anxiety or depression is your primary complaint rather than hot flashes, an SSRI or SNRI combined with CBT may address the core issue more directly than HRT would.
• Predominantly sleep-related symptoms: If insomnia is your biggest challenge, CBT-I (with or without bedtime gabapentin) may be more targeted and effective than adding systemic hormones.
• Personal preference: Some women simply prefer not to use hormone therapy, and that is a valid choice. Having effective alternatives means this preference does not require suffering in silence.
• Active liver disease: Both oral HRT and fezolinetant require consideration of liver function, but options like gabapentin, SSRIs, and CBT do not carry hepatic concerns.

It is also worth noting that some women use non-hormonal treatments alongside HRT. A woman on estrogen therapy who still has residual sleep problems might add CBT-I. Someone using HRT for hot flashes might also benefit from CBT for mood management. These approaches are complementary, not mutually exclusive.

Combining Approaches for Better Results

One of the most important things to understand about non-hormonal treatments is that they often work best in combination. Because no single non-hormonal option matches HRT’s ability to address multiple symptom domains simultaneously, a layered approach is frequently necessary to achieve adequate relief.

Here are some practical examples of how combinations might work:

• A breast cancer survivor might use fezolinetant for hot flashes, CBT-I for sleep, and vaginal moisturizers for dryness.
• A woman with hot flashes and mood instability might take venlafaxine (addressing both) and add gabapentin at bedtime specifically for night sweats and sleep.
• A woman who prefers to avoid prescription medications might start with CBT-Meno for hot flash distress, CBT-I for sleep, regular exercise, and vaginal moisturizers, and then add prescription treatments only if needed.

Work with your clinician to build a layered plan that addresses your most disruptive symptoms first. Perimenopause is a moving target, and your treatment plan should evolve as your symptoms change. What disrupts your life most at age 44 may be different from what bothers you most at 50.

Evidence at a Glance: A Practical Summary

Here is a summary of the non-hormonal options discussed in this article, organized by the symptom they address and the strength of evidence behind them.

Hot flashes and night sweats:

• Fezolinetant (Veozah): strong evidence, 60 to 65 percent reduction, FDA-approved for vasomotor symptoms
• Gabapentin: strong evidence, 45 to 70 percent reduction, best taken at bedtime
• Pregabalin: strong evidence, 50 to 65 percent reduction
• Venlafaxine/desvenlafaxine: strong evidence, 30 to 60 percent reduction
• Paroxetine (Brisdelle): strong evidence, 33 to 65 percent reduction, FDA-approved for vasomotor symptoms
• Clonidine: moderate evidence, 20 to 40 percent reduction
• CBT-Meno: strong evidence for reducing hot flash distress (not frequency)

Insomnia and sleep disruption:

• CBT-I: very strong evidence, first-line treatment for chronic insomnia
• Gabapentin/pregabalin: strong evidence, particularly helpful for sleep disrupted by night sweats

Mood and anxiety:

• SSRIs/SNRIs: strong evidence for depression and anxiety during menopause
• CBT: strong evidence for depression, anxiety, and adjustment to life changes

Vaginal dryness and painful intercourse:

• Low-dose vaginal estrogen: strong evidence, most effective option, minimal systemic absorption
• Vaginal moisturizers: moderate evidence, best for mild symptoms
• Lubricants: practical effectiveness, widely recommended

The Bottom Line

The non-hormonal treatment landscape for perimenopause is broader and more effective than many women realize. While no single non-hormonal option matches HRT’s ability to address multiple symptoms simultaneously, the combination of targeted prescription medications, evidence-based behavioral therapies, and practical vaginal care can provide meaningful, and sometimes substantial, relief.

The arrival of fezolinetant in 2023 marked a particularly important milestone. For the first time, women have access to a medication designed from the ground up to treat hot flashes without involving hormonal pathways. Combined with the well-established benefits of SSRIs, gabapentin, and CBT, this means that women who cannot or prefer not to use HRT have more effective options than at any point in history.

If you have been told, or have assumed, that your only choices are “take hormones or tough it out,” that is simply not accurate. Effective help exists. The key is working with a clinician who is knowledgeable about the full range of treatments, willing to take your symptoms seriously, and experienced enough to help you build a personalized, layered plan.

You deserve to feel better. And you have more tools available than you may have been led to believe.